Research Progress in Chemokine Ligand 13 as a Potential Therapeutic Target in the Tumor Microenvironment of Colorectal Cancer.

Colorectal cancer is one of the most common malignant tumors in the digestive system and the third leading cause of malignant tumor-related deaths globally.The lack of effective therapeutic drug targets and biomarkers has resulted in low survival rates of colorectal cancer patients.In recent years,increasing studies have shown that the expression of chemokine ligand 13 (CXCL13) in the tumor microenvironment is closely related to tumor progression,prognosis,and response to immunotherapy.Especially in colorectal cancer,CXCL13 exhibits great potential as a potential marker for immune checkpoint therapy and its related T-cell subpopulations as immunotherapeutic targets.In this article,we review the research progress in CXCL13 in terms of its biological properties,association with the tumor microenvironment,related T-cell subpopulations,and targeted therapeutic strategies.